+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Preimplantation Genetic Diagnosis Market: By Technology; By Product; By End User; By Application & By Region - Forecast 2016-2021

  • ID: 3973813
  • Report
  • 165 pages
  • IndustryARC
1 of 2
Preimplantation genetic diagnosis (PGD) can be defined as a medical procedure generally used prior to implantation in order to identify genetic defects within embryos created through in vitro fertilization and prevent certain diseases or disorders from being passed on to the child. Preimplantation genetic diagnosis is a newer treatment procedure and is gaining popularity due to increasing awareness amongst people across the world. However, higher cost of treatment is expected to be the key challenge in developing countries.

This report identifies the global preimplantation genetic diagnosis market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global preimplantation genetic diagnosis market.

Geographically North America dominated global preimplantation genetic diagnosis market due to advanced and well developed healthcare infrastructure and higher awareness about such treatments amongst population and practitioners. North America was followed by Europe and Asia-Pacific as second and third largest markets. Asia Pacific is projected to have fastest growth, owing to rapidly increasing population, rise in medical expenditure in developing nations such as China, and India in this region.
This report segments global preimplantation genetic diagnosis market on the basis of technology, product, end user, application and regional market as follows:
Preimplantation Genetic Diagnosis Market, By Product Type: Instrument and Reagent
Preimplantation Genetic Diagnosis Market, By Technology: Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Fluorescence In-situ Hybridization (FISH) and Comparative Genomic Hybridization (CGH)
The report has focused study on preimplantation genetic diagnosis market by basis of application as follows: HLA Typing, Inheritable Genetic Disorders, Chromosomal Abnormalities, Single Gene Disorders, Gender Identification and Sex Linked Disorders
The report has focused study on preimplantation genetic diagnosis market by basis of end-user as follows: Hospital, Diagnostic Lab, Research Lab, Academia
This report on preimplntation genetic diagnosis has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region
This report identifies all the major companies operating in the preimplantation genetic diagnosis market. Some of the major companies’ profiles in detail are as follows:
Abbott Laboratories, Inc. (U.S.)
F. Hoffmann-La Roche. Ltd. (Switzerland)
Genesis Genetics, LLC (U.S.)
Illumina, Inc. (U.S.)
Laboratory Corporation of America Holdings (U.S.)
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
Note: Product cover images may vary from those shown
2 of 2
1. Preimplantation Genetic Diagnosis Market – Market Overview

2. Executive Summary

3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis

4. Preimplantation Genetic Diagnosis Market– Market Forces
4.1. Drivers
4.1.1. Increasing preference for personalized medicine
4.1.2. Growing awareness related to genetic techniques
4.2. Restraints
4.2.1. Higher cost of treatment
4.3. Opportunities
4.4. Challenges
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition

5. Preimplantation Genetic Diagnosis Market – Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life cycle Analysis
5.5. Suppliers & Distributors

6. Preimplantation Genetic Diagnosis Market, By Technology
6.1. Polymerase Chain Reaction (PCR)
6.2. Next Generation Sequencing (NGS)
6.3. Fluorescence In-situ Hybridization (FISH)
6.4. Comparative Genomic Hybridization (CGH)

7. Preimplantation Genetic Diagnosis Market, By Product
7.1. Instrument
7.2. Reagent

8. Preimplantation Genetic Diagnosis Market, By End-User
8.1. Hospital
8.2. Diagnostic Lab
8.3. Research Lab
8.4. Academia

9. Preimplantation Genetic Diagnosis Market, By Application
9.1. HLA Typing
9.2. Inheritable Genetic Disorders
9.3. Chromosomal Abnormalities
9.4. Single Gene Disorders
9.5. Gender Identification
9.6. Sex Linked Disorders

10. Preimplantation Genetic Diagnosis Market, By Geography
10.1. Europe
10.1.1. Germany
10.1.2. France
10.1.3. Italy
10.1.4. Spain
10.1.5. Russia
10.1.6. U.K.
10.1.7. Rest of Europe
10.2. Asia Pacific
10.2.1. China
10.2.2. India
10.2.3. Japan
10.2.4. South Korea
10.2.5. Rest of Asia-Pacific
10.3. North America
10.3.1. U.S.
10.3.2. Canada
10.3.3. Mexico
10.4. Rest of the World (RoW)
10.4.1. Brazil
10.4.2. Rest of RoW

11. Preimplantation Genetic Diagnosis – Market Entropy
11.1. Expansion
11.2. Technological Developments
11.3. Merger & Acquisitions, and Joint Ventures
11.4. Supply- Contract

12. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
12.1. Abbott Laboratories, Inc. (U.S.)
12.2. F. Hoffmann-La Roche. Ltd. (Switzerland)
12.3. Genesis Genetics, LLC (U.S.)
12.4. Illumina, Inc. (U.S.)
12.5. Laboratory Corporation of America Holdings (U.S.)
12.6. Natera, Inc. (U.S.)
12.7. PerkinElmer, Inc. (U.S.)
12.8. Quest Diagnostics, Inc. (U.S.)
12.9. Reproductive Genetics Institute (U.S.)
12.10. Reprogenetics LLC (U.S.)
* More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"Financials would be provided on a best efforts basis for private companies"

13. Appendix
13.1. Abbreviations
13.2. Sources
13.3. Research Methodology
13.4. Bibiliography
13.5. Compilation of Expert Insights
13.6. Disclaimer
Note: Product cover images may vary from those shown
3 of 2